Roundup claim screener

Legal information only. This screener identifies potential claim eligibility based on general criteria. An attorney determines final qualification. See our full disclaimer.

Your Roundup claim evaluation

Connect with a Roundup attorney

A Roundup litigation attorney will review your case at no cost. No fee unless you win.

Roundup and Non-Hodgkin's lymphoma

Roundup is the world's most widely used herbicide. Its active ingredient, glyphosate, was classified as "probably carcinogenic to humans" by the International Agency for Research on Cancer (IARC) in 2015. Internal Monsanto documents revealed in litigation showed the company ghost-wrote scientific studies and worked to suppress research linking glyphosate to cancer.

In 2019, Bayer acquired Monsanto and inherited its Roundup liability. Bayer has since paid over $10 billion to settle approximately 100,000 Roundup claims. Despite settling, Bayer has continued selling Roundup and additional lawsuits are still being filed by people diagnosed after the settlement cutoff dates.

Who qualifies

The strongest Roundup claims involve people who used Roundup regularly for at least 2 years and were subsequently diagnosed with Non-Hodgkin's lymphoma (NHL) or a related blood cancer including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, or B-cell lymphoma. Farmers, landscapers, golf course workers, and homeowners who used Roundup extensively are all potential claimants.

Current litigation status

Bayer reached a settlement in 2020 covering many existing claims. New claims from people diagnosed after the settlement continue to be filed. Courts are still adjudicating individual cases that didn't participate in the settlement. An attorney can advise whether your claim falls under an existing settlement structure or warrants a new individual lawsuit.

Frequently asked questions

Yes. Residential use qualifies for Roundup claims, though occupational users (farmers, landscapers) who used it heavily over many years tend to have stronger cases due to higher cumulative exposure. For residential claims, attorneys look for regular use over multiple years - not just occasional spot spraying. If you used Roundup frequently in a large garden, on a farm, or for landscaping and developed NHL, you have a potential claim worth evaluating.

Yes. The 2020 Bayer settlement covered specific claimants who registered by certain deadlines. People diagnosed after those cutoffs, or who didn't participate in the settlement, can still file individual lawsuits. Bayer continues to face new Roundup litigation. An attorney can determine whether your claim falls under any existing settlement framework or requires a new individual filing.

Non-Hodgkin's lymphoma is the primary diagnosis in Roundup litigation, covering diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, and other NHL subtypes. Some attorneys are also evaluating claims for other blood cancers including multiple myeloma and leukemia, though these have a weaker evidence base in the current litigation. A confirmed NHL diagnosis is the strongest starting point.

Individual Roundup settlements have ranged from $5,000 to over $2 million depending on diagnosis severity, duration of use, and other damages factors. The 2019 trial verdicts that preceded the settlement reached $289 million, $80 million, and $2 billion (later reduced). Individual settlement values in the global program were lower but provided faster certainty. New individual cases outside the settlement may produce larger recoveries for serious diagnoses.

State statutes of limitations apply, typically 2 to 3 years from the NHL diagnosis date or from when you knew the cancer was linked to Roundup exposure. The discovery rule may extend the deadline if the connection wasn't reasonably knowable at diagnosis. Given that awareness of the Roundup-cancer link has grown significantly since 2015 and 2019, courts have applied the discovery rule in many cases. Contact an attorney to confirm your specific deadline.